Agave derived beverages with improved quality contain enhanced ratios of MAO B to MAO A inhibitors or enhanced concentration of inhibitor of MAO B.

Agave derived beverages with improved quality contain enhanced ratios of MAO B to MAO A inhibitors or enhanced concentration of inhibitor of MAO B.

The present invention provides compositions and methods for producing magnetic bionanocatalysts (BNCs) comprising metabolically self-sufficient systems of enzymes that include P450 monooxygenases or other metabolic enzymes and cofactor regeneration enzymes.

The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

The present disclosure is based on the discovery that cells enriched with mitochondria are useful for treating diseases and disorders. The present invention provides methods of identifying or detecting such cells enriched with exogenous mitochondria. Specifically, the identification or detection of mitochondria-enriched cells is determined by utilization of a substrate such as tryptamine. This includes determining levels of MonoAmine oxidase A (MAO-A), Mono Amine oxidase-B (MAO-B), glycerol-3-phosphate dehydrogenase or a combination thereof. The present invention also provides kits for the identification or detection of mitochondria-enriched cells.

The present invention provides recombinant Escherichia coli for producing glutarate, a construction method and use thereof. A double-plasmid recombinant bacterium is constructed through molecular biological means for co-expressing an aldehyde synthase (AAS) gene, an amine oxidase Mao (gene) and an aldehyde dehydrogenase (Glox) gene. The constructed expression plasmids are introduced into the Escherichia coli to reconstruct to obtain recombinant cells. A recombination strain for efficiently producing glutarate is obtained through amicillin resistance and kanamycin resistance combined plate screening. Efficient production of the glutarate is achieved by optimizing concentration of a substrate, cell concentration and a transformation temperature. L-lysine with a concentration of 30 g/L may be transformed into 19.65 g of glutarate through reactions for 30 h under transformation conditions that the cell concentration is 30 g/L, the pH value is 8 and 6 mM of NAD.sup.+ is additionally added, wherein a transformation rate may be 65.3%.

A pharmaceutical composition and method for treating brain cancer are provided. The method includes administering to a patient in need thereof an effective amount of one or more compounds that include moclobemide, clorgyline, clorgyline's Near-infra-red dye Monoamine Oxidase Inhibitor (NMI), and MHI 148-clorgyline, and their salt thereof. The composition and method are particularly effective in reducing the size of glioblastomas that are temozolomide (TMZ) resistant.

The present invention relates to the technical field of biosynthesis, and in particular to a method for preparing S-nicotine. Amine oxidase is utilized to oxidize 1-methylpyrrolidine into corresponding imine, and then the imine and nicotinic acid are condensed and decarboxylated under the catalysis of nicotine synthetase to obtain a final product S-nicotine. The S-nicotine having specific chirality can be obtained by means of two-step reaction in a reaction system, the synthetic route is short, the yield is high, the reaction conditions are mild, and large-scale production is easy to achieve; moreover, raw materials are wide in source, low in price, low in production cost and environmentally friendly, the production cost of nicotine is remarkably reduced, and the requirements of current green industrial production can be better satisfied.

A mechanism of monoamine oxidases (MAOs) driven epithelium-to-mesenchymal transition (EMT) is disclosed. Also disclosed are methods for treating cancer by inhibiting or suppressing MAOs in cancer cells. Novel MAOs inhibitors, such as small molecules, siRNA, shRNA, antisense oligonucleotides, aptamers, decoys, and pharmaceutical compositions useful for treating cancer by disrupting the workings of MAOs are provided. In particular, a class of conjugates formed by covalently conjugating near infrared dye 783, IR-780, and MHI-148 to a MAO inhibitor, such as clorgyline, with and without encapsulation it in a nanoparticle is provided. Other aspects of the invention include methods for forming the nano-conjugates, method for monitoring treatment progress in a cancer patient by monitoring the changes in MAO activity, methods for screening patients who are at risk of cancer or differentiating different forms of cancer by assaying the level and location of MAO activity.

A method of treating prostate cancer in a subject with biochemically recurrent prostate cancer is provided. The method includes administering to a subject in need thereof an effective amount of a pharmaceutical composition that includes phenelzine.